Categories: News

NYSE Content Advisory: Pre-Market update + Traders See 55% Chance Fed Holds Rates Steady

NEW YORK, Nov. 17, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on November 17th

- Advertisement -
  • Markets ended last week mixed, with the S&P 500 posting modest gains despite Thursday’s pullback. Investors spent the week recalibrating expectations around future Fed rate cuts.
  • Fed minutes from the October meeting drop Wednesday, potentially offering clues about a December rate move. Traders now see a 45% chance of a 25bps cut, down sharply from over 95% a month ago.
  • NVIDIA reports Wednesday, while NYSE-listed companies including Home Depot and Lowe’s offer insight into consumer strength. Plus, the delayed September jobs report arrives Thursday following the government’s reopening.


Opening Bell

Webster Financial Corporation (NYSE: WBS) celebrates its 90th anniversary of founding

- Advertisement -


Closing Bell

Canadian National Railway (NYSE: CNI) celebrates its 30th anniversary of listing

- Advertisement -


Click here to download the NYSE TV App 

- Advertisement -

Video – https://mma.prnewswire.com/media/2824744/NYSE_Market_Update_Nov_17.mp4
Logo – https://mma.prnewswire.com/media/2581322/5626087/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–traders-see-55-chance-fed-holds-rates-steady-302617168.html

- Advertisement -

Recent Posts

Maha Songkran World Water Festival 2026 opens in Bangkok

Five days of culture, music and water celebrations at Benchakitti Park reinforce UNESCO-recognised Songkran as…

5 hours ago

BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase…

15 hours ago

Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency

Los Angeles, CA, April 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational…

15 hours ago

Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management

SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF),…

19 hours ago

CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands

BEIJING, April 11, 2026 /PRNewswire/ -- CGTN published an article on the meeting between Xi…

19 hours ago